Search Site

Serge Przedborski, MD, PhD

Academic Appointments

  • Page and William Black Professor of Neurology (in Pathology and Cell Biology and Neuroscience)

Current Administrative Positions

  • Vice Chair of Research, Department of Neurology
  • Co-Director, Motor Neuron Center
  • Director, Columbia Translational Neuroscience Initiative (CTNI)
Serge Przedborski, MD, PhD

Dr. Przedborski's academic interests focus on the molecular and cellular biology of neurodegenerative disorders such as Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS). His ongoing research aims at understanding the contributions of cell-autonomous and non cell-autonomous mechanisms to neurodegeneration using both toxic and genetic experimental models of PD and ALS. In keeping with this goal, how alterations in mitochondrial biology, especially of mitochondrial dynamics and mitophagy, provoke degeneration of specific subpopulations of neurons is one of the main areas of research in the Przedborski laboratory. To what extent and by which mechanisms do non-neuronal cells, like microglia and astrocytes, participate in the demise of neurons in neurodegenerative disorders, such as PD and ALS, represent a second main line of research in this laboratory.

These research efforts are supported by federal grants from both NIH and the DoD as well as by several private agencies such as the Parkinson's Disease Foundation and the Thomas Hartman Foundation. Dr. Przedborski is a Senior Editor for the Journal of Neuroscience and an Associate Editor of Movement Disorders. He also serves as an ad hoc Reviewer for the National Institutes of Health, the Veterans Adminsration, the Department of Defense, the Canadian Medical Research Council, and various medical journals including Science, Nature, Nature Neuroscience, Neuron, the New England Journal of Medicine, and the Proceedings of the National Academy of Science USA.

My laboratory has concentrated its research efforts on experimental models of Parkinson's disease (PD) and of amyotrophic lateral sclerosis (ALS). Through the use of both in vitro and in vivo models of these two adult-onset neurodegenerative disorders, we have studied the contribution of death of specific subsets of neurons a series of both cell autonomous and non-cell autonomous mechanisms.

Among the cell autonomous mechanisms of neurodegeneration, we have paid particular attention to the role of mitochondria, fist by studying the link of defect in bioenergetic and neuronal death; then by linking respiratory defect to program cell death, and more recently by studying defect in mitophagy and neuronal death.  Our recent results have shown that PINK1 and Parkin interact to modulate the turnover of defective mitochondria and that in presence of PINK1 and/or Parkin mutations, mitochondrial quality control mechanisms are defective. Currently, we thus try to understand PINK1 normal function and how it communicates with Parkin. We also study the actual molecular basis of mitophagy and how any defect in such mechanism of quality control could cause neurodegeneration.

Among the non-cell autonomous mechanisms of neurodegeneration, we have first studied the actual role and molecular determinants of neuroinflammation, i.e. how activated microglia and reactive astrocytes could mediate neuronal death. More recently, we have found that astrocytes derived from both experimental models of disease such as ALS and from patients can provoke the death of specific neurons. Currently, we are thus searching at identifying the nature of the toxic factor(s) mediating this neurodegeneration phenomenon; at defining the molecular cascade of death engaged within specific of neurons upon exposure to toxic astrocytes, and at miniaturizing this in vitro model of ALS to use it for high-throughput screening of small molecules library.   

Departmental Appointments

  • Department of Pathology & Cell Biology
  • Department of Neurology
    Division of Movement Disorders

Areas of Expertise

  • Neurology

Languages Spoken

  • French

Education & Training

  • Universite Libre de Bruxelles Faculty of Medicine (Belgium)
  • Residency: Universite Libre de Bruxelles (Belgium)
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Centers/Institutes/Programs

  • Columbia Translational Neuroscience Initiative
  • Motor Neuron Center

Provider Affiliations

  • NewYork-Presbyterian/Columbia

This provider does not accept new patients

Contact Phone Number: (212) 342-4119

Lab Locations

  • 630 West 168th Street
    P&S 5-420
    New York, NY 10032
    Phone:
    (212) 342-4119
    Lab Phone:
    (212) 305-8689
    Email:
    sp30@cumc.columbia.edu

Research Interests

  • Neurodegeneration
  • Neurobiology of Disease
  • Molecular and Cellular Biology of Neurodegeneration
  • Parkinson's Disease
  • Motor Neuron Biology and Diseases
  • Amyotrophic Lateral Sclerosis
  • Mitochondria Biology and Disease
  • Mitophagy
  • Neuroinflammation
  • Microglia
  • Astrocytes
  • Apoptosis
  • Necroptosis
  • Bioinfomatics
  • High-throughput Screening
  • Stem Cell Biology
  • Neural Degeneration and Repair
  • Motor Systems

NIH Grants

  • NON-CELL AUTONOMOUS ROLE OF SYNUCLEIN IN NEURODEGENERATION (Federal Gov)

    Feb 1 2017 - Jan 31 2019

    ROLE OF MMP-9 IN SELECTIVE MOTOR NEURON DEGENERATION IN ALS (Federal Gov)

    Jun 1 2013 - Mar 31 2018

    ENHANCING ANIMAL CARE IN A NEW HIGH-THROUGHPUT RODENT BEHAVIOR ANALYSIS CORE FACILITY (Federal Gov)

    Mar 15 2016 - Mar 14 2017

    BIOGEN GRANT (Private)

    Nov 25 2015 - Nov 24 2016

    A CELL-BASED ASSAY TO IDENTIFY NEUROPROTECTIVE MOLECULES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (Federal Gov)

    Sep 30 2013 - Sep 29 2016

    SIGNALING PATHWAYS OF NECROPTOSIS (Federal Gov)

    Sep 30 2014 - Aug 31 2016

    PARKINSONS DISEASE FOUNDATION RESEARCH CENTER GRANT (Private)

    Jul 1 2000 - Jun 30 2016

    OCULOMOTOR RESISTANCE IN ALS:PROJECT 2-NOVEL MARKERS OF SELECTIVE AND VULNERABILITY (Private)

    Jan 1 2013 - Dec 31 2015

    MECHANISMS OF DOPAMINE NEURON DEGENERATION (Federal Gov)

    Aug 1 2000 - Jul 31 2015

    PARKINSONS DISEASE FOUNDATION RESEARCH CENTER GRANT (Private)

    Jul 1 2000 - Jun 30 2015

    EVALUATING HMG-COA REDUCTASE AS A THERAPEUTIC TARGET IN ALS (Federal Gov)

    Feb 1 2013 - Jan 31 2015

    C-JUN-N-TERMINAL KINASE (JNK) FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (Federal Gov)

    Sep 30 2012 - Sep 29 2014

    PARKINSON S DISEASE FOUNDATION RESEARCH CENTE (Private)

    Jul 1 2000 - Jun 30 2014

    PARKINSON S DISEASE FOUNDATION RESEARCH CENTE (Private)

    Jul 1 2000 - Jun 30 2014

    PROINFLAMMATORY ENZYMES IN AMYTROPHIC LATERAL SCLEROSIS (Federal Gov)

    Aug 1 2001 - Feb 28 2014

    PRE-CLINICAL TESTING OF NECROSTATIN AS A POTENTIAL SMALL MOLECULE FOR THE TREATMENT OF ALS (Federal Gov)

    Jan 15 2011 - Dec 31 2013

    DEFECTS OF MITOCHONDRIAL DYNAMICS IN ALS (Federal Gov)

    Jan 15 2009 - Dec 31 2013

    CELL-BASED ASSAYS FOR THE SCREENING OF NEUROPROTECTIVE SMALL MOLECULE FOR ALS (Private)

    Sep 1 2012 - Aug 31 2013

    SPINAL MUSCULAR ATROPHY (SMA): DISEASE PHENOTYPE AND MECHANISMS (Federal Gov)

    Aug 1 2009 - Aug 31 2013

    PRE-CLINICAL TESTING OF NEW HYDROXYBUTYRATE ANALOGUES (Federal Gov)

    Jul 1 2010 - Jun 30 2013

    PARKINSONS DISEASE FOUNDATION (PDF) RESEARCH CENTER GRANT 20 10-2011 (Private)

    Jul 1 2009 - Jun 30 2013

    PARKINSONS DISEASE FOUNDATION (PDF) RESEARCH CENTER GRANT 2012-2013 (Private)

    Jul 1 2009 - Jun 30 2013

    LOCALIZATION OF A-SYNUCLEIN IN MITOCHONDRIAL-ASSOCIATED ER MEMBRANES (MAM): A NEW INSIGHT INTO THE PATHOGENESIS OF PD (Private)

    Jun 30 2012 - Jun 29 2013

    INTERACTION OF SYNUCLEIN AND INFLAMMATION IN DOPAMINERGIC NEURODEGERATION (Federal Gov)

    Jun 30 2008 - Jun 29 2013

    PINK1 ROLE IN MITOPHAGY (Private)

    Jun 1 2011 - May 31 2013

    HUMAN IPS CELLS AS A MODEL TO STUDY ALS PATHOGENESIS (NY State Gov)

    Jan 1 2009 - Dec 31 2012

    NEUROPROTECTIVE SMALL MOLECULES FOR THE TREATMENT OF AMYOTRO PHIC LATERAL SCLEROSIS (Federal Gov)

    Sep 1 2008 - Sep 30 2012

    PARKINSON DISEASE IPS CELL LINE RESEARCH CONSORTIUM (Federal Gov)

    Sep 30 2009 - Aug 31 2012

    PARKINSON''S DISEASE IPS CELL LINE RESEARCH (Federal Gov)

    Sep 30 2009 - Aug 31 2012

    PATHOLOGICAL INTERACTIONS OF ALPHA- SYNUCLEIN, MITOCHONDRIA AND PESTICIDES IN PD MODELS (Federal Gov)

    Sep 30 2009 - Jul 31 2012

    A NOVEL CELL-BASED HIGH-THROUGHPUT ASSAY FOR ALS (Federal Gov)

    Mar 1 2009 - Feb 29 2012

    NADPH-OXIDASE MPTP SUBMISSION FOR THE HARTMAN FOUNDATION (Private)

    Jun 1 2008 - May 31 2011

    CHARACTERIZATION OF AN IN VITRO MODEL OF MOTOR NEURON DEGENE RATION IN SPINAL MUSCULAR ATROPHY (Private)

    Apr 1 2009 - Mar 31 2011

    PROGRAM PROJECT ON THE PATHOGENESIS AND TREATMENT OF PARKINS ON S DISEASE (Federal Gov)

    Dec 1 2002 - Dec 31 2009

Publications

Since 2010 only:

  1. Fedorowicz MA, de Vries-Schneider RL, Rüb C, Becker D, Huang Y, Zhou C, Alessi Wolken DM, Voos W, Liu Y, Przedborski S. Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy. EMBO Rep. 2013 Dec 19. [Epub ahead of print] PubMed PMID: 24357652.
  2. Roybon L, Lamas NJ, Garcia-Diaz A, Yang EJ, Sattler R, Jackson-Lewis V, Kim YA, Kachel CA, Rothstein JD, Przedborski S, Wichterle H, Henderson CE. Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. Cell Rep. 2013 Sep 12;4(5):1035-48. doi: 10.1016/j.celrep.2013.06.021. Epub 2013 Aug 29. PubMed PMID: 23994478.
  3. Di Paolo G, Przedborski S. When Schwann cells conspire with mitochondria, neighboring axons are under attack by glia-derived neurotoxic lipids. Neuron. 2013 Mar 6;77(5):801-3. doi: 10.1016/j.neuron.2013.02.016. PubMed PMID: 23473310.
  4. Teng YD, Benn SC, Kalkanis SN, Shefner JM, Onario RC, Cheng B, Lachyankar MB, Marconi M, Li J, Yu D, Han I, Maragakis NJ, Lládo J, Erkmen K, Redmond DE Jr, Sidman RL, Przedborski S, Rothstein JD, Brown RH Jr, Snyder EY. Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med. 2012 Dec 19;4(165):165ra164. doi: 10.1126/scitranslmed.3004579. PubMed PMID: 23253611.
  5. Gonzalez-Reyes LE, Verbitsky M, Blesa J, Jackson-Lewis V, Paredes D, Tillack K, Phani S, Kramer ER, Przedborski S, Kottmann AH. Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit. Neuron. 2012 Jul 26;75(2):306-19. doi: 10.1016/j.neuron.2012.05.018. PubMed PMID: 22841315; PubMed Central PMCID: PMC3408586.
  6. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Torres E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Daley L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA, Trojanowski JQ, Lee VM, Marder K, Surmeier DJ, Wszolek ZK, Przedborski S, Krainc D, Dawson TM, Isacson O. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med. 2012 Jul 4;4(141):141ra90. doi: 10.1126/scitranslmed.3003985. PubMed PMID: 22764206; PubMed Central PMCID: PMC3462009.
  7. Kariya S, Re DB, Jacquier A, Nelson K, Przedborski S, Monani UR. Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies. Hum Mol Genet. 2012 Aug 1;21(15):3421-34. doi: 10.1093/hmg/dds174. Epub 2012 May 11. PubMed PMID: 22581780; PubMed Central PMCID: PMC3392116.
  8. Becker D, Richter J, Tocilescu MA, Przedborski S, Voos W. Pink1 kinase and its membrane potential (Deltaψ)-dependent cleavage product both localize to outer mitochondrial membrane by unique targeting mode. J Biol Chem. 2012 Jun 29;287(27):22969-87. doi: 10.1074/jbc.M112.365700. Epub 2012 Apr 30. PubMed PMID: 22547060; PubMed Central PMCID: PMC3391148.
  9. Magrané J, Sahawneh MA, Przedborski S, Estévez ÁG, Manfredi G. Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons. J Neurosci. 2012 Jan 4;32(1):229-42. doi: 10.1523/JNEUROSCI.1233-11.2012. PubMed PMID: 22219285; PubMed Central PMCID: PMC3566782.
  10. Gilkerson RW, De Vries RL, Lebot P, Wikstrom JD, Torgyekes E, Shirihai OS, Przedborski S, Schon EA. Mitochondrial autophagy in cells with mtDNA mutations results from synergistic loss of transmembrane potential and mTORC1 inhibition. Hum Mol Genet. 2012 Mar 1;21(5):978-90. doi: 10.1093/hmg/ddr529. Epub 2011 Nov 11. PubMed PMID: 22080835; PubMed Central PMCID: PMC3277306.
  11. Schon EA, Przedborski S. Mitochondria: the next (neurode)generation. Neuron. 2011 Jun 23;70(6):1033-53. doi: 10.1016/j.neuron.2011.06.003. Review. PubMed PMID: 21689593; PubMed Central PMCID: PMC3407575.
  12. Perier C, Bové J, Dehay B, Jackson-Lewis V, Rabinovitch PS, Przedborski S, Vila M. Apoptosis-inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins. Ann Neurol. 2010 Aug;68(2):184-92. doi: 10.1002/ana.22034. PubMed PMID: 20695011.
  13. Wichterle H, Przedborski S. What can pluripotent stem cells teach us about neurodegenerative diseases? Nat Neurosci. 2010 Jul;13(7):800-4. doi: 10.1038/nn.2577. PubMed PMID: 20581816; PubMed Central PMCID: PMC3063524.
  14. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci. 2010 Jan 20;30(3):1166-75. doi: 10.1523/JNEUROSCI.3944-09.2010. PubMed PMID: 20089925; PubMed Central PMCID: PMC2880868.
  15. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci. 2009 Jul;12(7):826-8. doi: 10.1038/nn.2349. Epub 2009 Jun 7. PubMed PMID: 19503083; PubMed Central PMCID: PMC2845930.

For a complete list of publications, please visit PubMed.gov